Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and Pharmacokinetics of Multiple Doses of MN-08 in Healthy Subjects
NCT05660863Phase 1Not yet recruiting
- Sponsor
- Guangzhou Magpie Pharmaceutical
- Start
- Sep 2027
- Primary completion
- Mar 2028
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of nitronaphthazine in pulmonary arterial hypertension (PAH) (2 cohorts), sponsored by Guangzhou Magpie Pharmaceutical. Primary endpoints: Incidence and severity of Treatment-Emergent Adverse Events and Serious Adverse Events and Incidence and severity of treatment-related adverse events. Planned start Sep 2027; status: not yet recruiting.
02
Drugs
nitronaphthazine
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT05660863.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05660863.